Every 10-Q that Jazz Pharmaceuticals, Inc. (JAZZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JAZZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAZZ filings page.
Jazz Pharmaceuticals reported second-quarter 2026 revenues of $1,208.3 million, up from $1,045.7 million a year earlier, and net income of $192.8 million versus a net loss of $718.5 million. For the first six months, revenues were $2,277.2 million and net income was $485.9 million, compared with a loss of $811.0 million in the prior-year period. Results reflect $77.0 million of acquired in-process R&D versus $905.4 million last year and a $122.8 million gain on sale of a priority review voucher.
Product sales reached $1,156.1 million, led by Xywav at $471.2 million, Epidiolex/Epidyolex at $292.1 million, and oncology medicines at $362.3 million, including Zepzelca, Rylaze/Enrylaze, Defitelio, Modeyso and Ziihera. U.S. revenues were $1,077.9 million. Exiting the quarter, there were approximately 17,125 active Xywav patients, including about 11,275 with narcolepsy and 5,850 with idiopathic hypersomnia.
Jazz generated $823.9 million of operating cash flow in the first half, ending June 30, 2026 with $1,619.8 million in cash and cash equivalents and $580.0 million in investments. Total debt declined to $4,351.4 million from $5,358.3 million after repaying the $1.0 billion 2026 exchangeable notes, issuing 1.89 million shares for the conversion premium, while the $1.0 billion 2030 notes became exchangeable and were classified as current. During the quarter, Jazz paid $56.0 million upfront to AbCellera for a multispecific antibody collaboration and $21.0 million to acquire remaining rights to JZP898 from Werewolf, both expensed as acquired in-process R&D.
Jazz Pharmaceuticals reported sharply improved results for the quarter ended March 31, 2026. Total revenues rose to $1,068.9 million from $897.8 million, driven by higher product sales across sleep, epilepsy and oncology franchises.
Net income reached $293.1 million, compared with a net loss of $92.5 million a year earlier, helped by a $122.8 million gain on the sale of a rare pediatric disease priority review voucher and lower selling, general and administrative expenses. Cash and cash equivalents increased to $1,844.3 million, while total debt remained around $5.35 billion, leaving the company with significant liquidity to support its rare disease portfolio and R&D pipeline.
Jazz Pharmaceuticals plc reported higher Q3 results while reshaping its portfolio and balance sheet. Total revenue was $1,126,107, up from $1,054,969 a year ago, driven by product sales. Quarterly net income reached $251,412 versus $215,055 last year as a large income tax benefit offset higher operating costs.
Year to date, the company booked a net loss, reflecting significant acquired in‑process R&D tied to the April acquisition of Chimerix for cash consideration of $944.2 million. Operating cash flow remained strong at $993,255 for the nine months. Cash and cash equivalents were $1,326,070 with investments of $720,000. Total debt stood at $5,361,161, following a voluntary $750.0 million term‑loan repayment in January; the 2026 notes now sit in current maturities.
Pipeline and portfolio updates include FDA approval in October 2025 expanding Zepzelca’s maintenance use in extensive‑stage SCLC, FDA accelerated approval of Modeyso in August 2025, and prior U.S./EU authorizations for Ziihera. In August 2025, Jazz licensed SAN2355 from Saniona with a $42.5 million upfront, expensed to IPR&D.
Quarter ended June 30, 2025: Jazz Pharmaceuticals reported total revenues of $1,045,712 for Q2 2025 (product sales $985,571; royalties/contract $60,141), up modestly versus Q2 2024. Operating loss was $686,392 for the quarter, driven primarily by a $905,362 acquired in‑process R&D expense related to the April 21, 2025 Chimerix acquisition. Net loss for the quarter was ($718,470) (basic EPS ($11.74)).
Balance sheet and cash flow: Cash and cash equivalents declined to $1,189,880 from $2,412,864 at 12/31/2024, reflecting the Chimerix purchase (total cash consideration $944.2M) and other investing/financing uses. Total debt outstanding was $5,364,094 with the current portion increasing to $1,028,478 (2026 Notes included). Total shareholders' equity fell to $3,706,359. Net cash provided by operating activities for six months was $518,639; net cash used in investing was $809,951; financing used $937,991.
Other material items: Goodwill rose to $1,843,974; finite‑lived intangible assets net $4,768,987; five customers represented 81% of gross accounts receivable (ESSDS 41%). Foreign currency translation produced a quarter FX gain of $299,790 to other comprehensive income.